TheraVet Reports an 99% Increase in BIOCERA-VET® Units Sold in Q4 2023
23 January 2024 - 5:30PM
Business Wire
- BIOCERA-VET® (whole line) units sold are up 99% Year-on-Year
& up 27% Quarter-over-Quarter in Q4 2023; they are up 90%
Year-on-Year for H2 2023
- BIOCERA-VET® OSTEOSARCOMA unit sales up 145% Year-on-Year for
H2 2023 and up 38% Quarter-over-Quarter in Q4 2023
Regulatory News:
TheraVet (ISIN: BE0974387194 – ticker: ALVET), a
pioneering company in the management of osteoarticular diseases in
pets, announces significant sales progression for its
BIOCERA-VET® product range in the 4th quarter of 2023 year-on-year
and quarter over quarter.
The number of BIOCERA-VET® units sold increased 99% in the
fourth quarter of 2023 as compared to the same period in 2022
and 27% as compared to the third quarter of 2023. Over
the second half of 2023, BIOCERA-VET® units sold progressed
90% as compared to the same period of 2022.
BIOCERA-VET® BONE SURGERY1 accounted for 80% of the units sold
and BIOCERA-VET® OSTEOSARCOMA RTU for the remaining 20%. As for the
third quarter, BONE SURGERY RTU 3x1cc and OSTEOSARCOMA RTU 2x12cc
have significantly contributed to these figures. BIOCERA-VET® COMBO
CLEAN launched in Europe and United-States in May and October 2023
respectively already accounted for 5% of a total unit sold in 2023.
In the 4th quarter of 2023, BIOCERA-VET® BONE SURGERY unit sales
were up 101% compared to the same period of 2022 and up 24%
compared to previous quarter; they increased 80% over 2H 2023
as compared to H2 2022.
BIOCERA-VET® OSTEOSARCOMA RTU sales increased 145%
Year-on-Year over the second half of 2023, and 38%
Quarter-over-Quarter for the 4th quarter 2023.
Rapidly progressing, North America (USA and Canada) represents
21% of the units sold over the 2H 2023 (vs. 12% in H2 2022).
As communicated, the Company continued its important commercial
efforts during the last quarter 2023 resulting in a continue
progression of the sales.
Enrico Bastianelli, Chief Executive Officer of TheraVet,
stated: “The very good figures of fourth quarter 2023 confirm
the positive sales dynamic reported for the previous quarter. Our
commercial and marketing efforts resulted in significant
progression of the sales. The Company took advantage of this
positive trend to continue the expansion of the distribution in
Europe already started with Italy and Germany recently but also on
expanding its product portfolio in 2024.”
About TheraVet SA TheraVet is a veterinary biotechnology
company specializing in osteoarticular treatments for companion
animals. The Company develops targeted, safe and effective
treatments to improve the quality of life of pets suffering from
joint and bone diseases. For pet owners, the health of their pets
is a major concern and TheraVet’s mission is to address the need
for innovative and curative treatments. TheraVet works closely with
international opinion leaders in order to provide a more effective
response to ever-growing needs in the field of veterinary medicine.
TheraVet is listed on Euronext Growth® Paris and Brussels, has its
head office in Belgium (Gosselies) with a US subsidiary. For more
information, visit the TheraVet website or follow us on LinkedIn /
Facebook / Twitter
About BIOCERA-VET In close collaboration with an
international scientific board, THERAVET® has developed a new line
of calcium-phosphate and biological bone substitutes, BIOCERA-VET®.
BIOCERA-VET® is a full range of innovative, easy-to-use, efficient
& cost-effective bone substitutes indicated in bone surgeries
where a bone graft is required and as a palliative alternative in
the management of canine osteosarcoma. Based on extremely promising
clinical results, this line offers the possibility of a better,
more convenient and more efficient orthopedic surgery. BIOCERA-VET®
is declined in different lines:
- BIOCERA-VET® BONE SURGERY RTU, a ready-to-use highly injectable
self-hardening calcium-phosphate cement
- BIOCERA-VET® SMARTGRAFT, a naturally osteoconductive bone
graft
- BIOCERA-VET® GRANULES, an affordable biocompatible
calcium-phosphate bone substitute
- BIOCERA-VET® OSTEOSARCOMA RTU, a ready-to-use highly injectable
calcium-phosphate bone substitute for cementoplasty
- BIOCERA-VET® COMBO-CLEAN, a local and long-lasting antibiotic
delivery calcium-phosphate bone substitute
For more information, visit BIOCERA-VET website.
__________________________________ 1 BIOCERA-VET BONE SURGERY
(BS) line includes 6 references: BS RTU 1cc, BS RTU 3cc, BS RTU
3*1cc, Granules, Smartgraft and COMBO CLEAN products.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240122913627/en/
TheraVet Chief Operating Officer Sabrina Ena
investors@thera.vet Tel: +32 (0) 71 96 00 43
NewCap Investor Relations and Financial Communications
Théo Martin / Nicolas Fossiez theravet@newcap.eu Tel: +33 (0)1 44
71 94 94 Press Relations Arthur Rouillé theravet@newcap.eu Tel: +33
(0)1 44 71 00 15
NewCap Belgique Press Relations Laure-Eve Monfort
lemonfort@thera.vet Tel: + 32 (0) 489 57 76 52
TheraVet (EU:ALVET)
Historical Stock Chart
From Mar 2024 to Apr 2024
TheraVet (EU:ALVET)
Historical Stock Chart
From Apr 2023 to Apr 2024